The University of North Carolina at Chapel Hill

Other

Synecor LLC

University of Illinois

North Carolina State University

Micell Technologies, Inc.

Align Technology, Inc.

Carbon3d, Inc.

Epidestiny, Inc.

Smithkline Beecham Corporation

Liquidia Technologies, Inc.

Joseph Desimone

Edward T Samulski

Jason P Rolland

Michael Scott Williams

Ginger Denison Rothrock

Benjamin Maynor

Ruben Guillermo Carbonell

Yogen Saunthararajah

Richard Glenn

Jeffrey A Smith

Kevin D Holbrook

R Jude Samulski

Ansley E Dennis

Larken Elizabeth Euliss

James B McClain

Saad A Khan

Joseph R Royer

George W Roberts

Robert Eugene Tricca

Mary E Napier

Matthew Craig Parrott

Richard J Spontak

Paul A Charpentier

Brian J Novick

James Byrne

James P DeYoung

Timothy J Romack

Ashish A Pandya

Alexander Ermoshkin

Santhosh Vadivelu

Teri Anne Walker

Henry Lau

Jason S Keiper

Joel Tepper

Srinivas Siripurapu

Mathew Finniss

Mary Napier

Jonathan Pillai

Stephen R Quake

Hiroshi Shiho

T Mark McCleskey

Eva Rachel Birnbaum

Nikita Ermoshkin

Paul Raphael Resnick

William Tumas

Stephen M Gross

Jonathan L Kendall

Jeremy Richard Lizotte

Jen Jen Yeh

Michael Van Dam

Andrew J Murphy

Yizeng Ni

Florence E Henon

Kimberly R Powell

Sara Naomi Paisner

Ginger M Denison Rothrock

Stephanie A Crette

Ramone Givens

Robby A Petros

Terri Johnson Carson

John F Miller

Han-Chao Wei

Larkin E Euliss

Sharon Wells

Terri J Carson

Christopher L McAdams

Yvon J Gay

Jason Yarbrough

Derek A Schorzman

Stuart Williams

Meredith Earl

Zhilian Zhou

Matt Parrott

Lukas Miller Roush

Embodiments of compositions and methods for the treatment of blood disorders and malignancies in a subject are described herein. In one embodiment, a composition for the treatment of a blood disorder or a malignancy in a subject comprises decitabine, tetrahydrouridine, and an excipient. In another embodiment, a method for the treatment of a blood disorder or a malignancy in a subject comprises the oral administration of a composition comprising decitabine and tetrahydrouridine. In some examples, the composition may be administered 1-3 times weekly.

Compositions comprising decitabine and tetrahydrouridine and uses thereof

Compositions comprising decitabine and tetrahydrouridine or 5-azacytidine and tetrahydrouridine for the treatment of cancer are disclosed. The compositions in the form of a pill is administered to a human subject sequentially or alternately guided by the measurement of predictive biomarkers.

Compositions containing decitabine, 5azacytidine and tetrahydrouridine and uses thereof

The presently disclosed subject matter describes the use of fluorinated elastomer-based materials, in particular perfluoropolyether (PFPE)-based materials, in high-resolution soft or imprint lithographic applications, such as micro- and nanoscale replica molding, and the first nano-contact molding of organic materials to generate high fidelity features using an elastomeric mold. Accordingly, the presently disclosed subject matter describes a method for producing free-standing, isolated nanostructures of any shape using soft or imprint lithography technique.

Methods for fabricating isolated micro- or nano-structures using soft or imprint lithography

Compositions containing decitabine, 5Azacytidine and tetrahydrouridine and uses thereof

A method and system for combination therapy utilizing local drug delivery and radiotherapy at a target site of body tissue are provided. The delivery system comprises a source electrode adapted to be positioned proximate to a target site of internal body tissue. A counter electrode is in electrical communication with the source electrode, and is configured to cooperate with the source electrode to form a localized electric field proximate to the target site. A cargo may be delivered to the target site when exposed to the localized electric field. Radiotherapy is applied to the target site in combination with the local drug delivery.

Combined local delivery of therapeutic agents using interventional devices and radiation

A delivery system for local drug delivery to a target site of internal body tissue is provided. The delivery system comprises a source electrode adapted to be positioned proximate to a target site of internal body tissue. A counter electrode is in electrical communication with the source electrode, and is configured to cooperate with the source electrode to form a localized electric field proximate to the target site. A reservoir is configured to be disposed such that the reservoir is capable of interacting with the localized electric field. The reservoir is configured to carry a cargo capable of being delivered to the target site when exposed to the localized electric field. Associated methods are also provided.

Interventional drug delivery system and associated methods

Asymmetric bifunctional silyl (ABS) monomers comprising covalently linked pharmaceutical, chemical and biological agents are described. These agents can also be covalently bound via the silyl group to delivery vehicles for delivering the agents to desired targets or areas. Also described are delivery vehicles which contain ABS monomers comprising covalently linked agents and to vehicles that are covalently linked to the ABS monomers. The silyl modifications described herein can modify properties of the agents and vehicles, thereby providing desired solubility, stability, hydrophobicity and targeting.

Asymmetric bifunctional silyl monomers and particles thereof as prodrugs and delivery vehicles for pharmaceutical, chemical and biological agents

Discrete micro and nanoscale particles are formed in predetermined shapes and sizes and predetermined size dispersions. The particles can also be attached to a film to form arrays of particles on a film. The particles are formed from molding techniques that can include high throughput and continuous particle molding.

Isolated and fixed micro and nano structures and methods thereof

Growing community of inventors

Chapel Hill, NC, United States of America

Joseph Desimone